Phase 4 N=17 Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes
Type 1 Diabetes
Primary: Insulin Sensitivity by Hyperinsulinemic Euglycemic Clamp — 3.27; 3.46 mg/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo
Type 1 Diabetes Mellitus
Primary: Adverse Events — 5; 6; 10; 4 Number of AE
Phase 2 N=36 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
N/A N=1,500 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Coronary Disease · Coronary Stenosis
Primary: MACCE — 80; 51 Participants — p=0.35
Phase 1 N=38 Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
Anxiety Disorders
Primary: Maximum Observed Plasma Concentration (Cmax) of Paroxetine — 8.39; 8.83 Nanograms per milliliter
Phase 3 N=158 THINC-it Vortioxetine - Sensitivity to Change
Major Depressive Disorder · Cognitive Change
Primary: Cognition Measured Using the THINC-it Tool — -0.05; -0.12; 0.12; 0 z-score
Phase 3 N=65 Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Oropharynx Cancer
Primary: Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up — 20.1; 29.1…
N/A N=86 A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
HIV · Hepatitis C
Primary: Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry (PAT) — 1.98; 2.15 ratio
N/A N=47 Home Telemonitoring for Patients With Lung Cancer
Lung Cancer
Primary: Changes in Telemonitor Data From Baseline: Temperature — 97.05 Degrees Fahrenheit
Phase 2 N=12 COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Lymphangioleiomyomatosis (LAM)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 11 Participants
Phase 3 N=152 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16 — 43.7 percentage of participants
Phase 3 N=1,444 A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.20; -2.37; -1.34 Percentage of HbA1c — p=<0.001
Phase 2 N=105 A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Ovarian Neoplasms
Primary: Progression Free Survival (PFS) Rate — 62 Percentage of participants
Phase 2 N=30 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
Portal Hypertension · Liver Cirrhosis
Primary: Safety (Incidence and Severity of Adverse Events) — 23; 2 Number of adverse events
Phase 3 N=610 Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
Dry Eye Syndrome
Primary: Ocular Discomfort Scale — -0.6; -0.6 units on a scale